Sidney,
The answer is provided by Mr. Gallup in his recent letter to shareholders for July '98. Don't let your patience run out now after four (4) years.
immucor.com
This is a powerful statement by Mr. Gallup:
"While our 1998 fiscal results are not yet final, we finished the year with strong growth in sales. Bear in mind that this growth took place without our new instrument product line even being available for sale in the US! That's why, in our new fiscal year, we're excited about the potential for solid, double-digit growth-not just in revenue, but in earnings, as well."
Additionally, here are two projections regarding sales and revenues from the Yahoo! Immucor Message Board:
Earnings and Profit
technetx
Jul 18 1998
5:35PM EDT
I agree , earnings will increase significantly, especially the quarter reported in January. Rosys, Dias, ABS and I-Trac sales will all be working for BLud. Very hard to predict earnings now.
The selling price for the ABS is between $80,000 -110,000. There will be liberal discounts IMO. The reagents are the real money makers.
Not every account will be a new account so to include a new 50K reagent trail with each ABS placement is not totally accurate. Some of these accounts have already been using reagents with the older techniques, probably close to 50K per year in reagents (I think the ABS does use slightly more reagents...not sure)
Also, I think we will be in the 20's long before next July.
Re: Jerboal
alexporterIs1
Jul 17 1998
5:02PM EDT
My research indicates that Immucor's cost for each ABS 2000 is 40 K. This means we are looking at 60 - 70 K profit per machine. Add that to a reagent trail of nearly 50 K per year. That's 110 K or .013 per share per ABS 2000. Multiply that by Gallup's conservative 1 per week for 6 months 2 per week after that and we get 1.01 per share. Add in Roysis and non ABS 2000 reagent sales and we are looking REAL GOOD. I think we may be on to something here.
Regards,
Tom |
